
Overview
Provides guidance on the Pharmaceutical Development section for regulatory submissions [1]. Outlines Quality by Design (QbD) principles, design space, and control strategies to ensure product quality [2, 3]. G-Rex® is not referenced in this document.
What this paper found
ICH Q8(R2) sets out what a manufacturer should present in the Pharmaceutical Development section of a marketing application, with the aim of designing a quality product and a process that consistently delivers its intended performance. It stresses that the knowledge gained, not the volume of data, underpins science-based submissions. The annex describes quality by design: defining a quality target product profile, identifying critical quality attributes, assessing risk to link material attributes and process parameters to those attributes, and establishing a design space and a control strategy. Greater scientific understanding can support more flexible regulatory approaches, including real-time release testing and managing changes within an approved design space.
Note: The guideline states that it does not apply to submissions for drug products during the clinical research stages, although its principles are important to consider then.
It is the knowledge gained and submitted to the authorities, and not the volume of data collected, that forms the basis for science- and risk-based submissions and regulatory evaluations. — ICH Expert Working Group
Study details
- Authors
- ICH Expert Working Group
- Institution
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
- Year
- 2009
- Cell type(s)
- Other
Explore related
Full citation
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical Development Q8(R2). 2009.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.